Cardiff Lexington Corp. reported third quarter 2025 financial results, with total revenue rising 125.6% to $3.1 million compared to the same period in 2024. Gross profit increased 437.8% to $1.9 million, and income from continuing operations grew 209.9% to $643,000. Non-GAAP adjusted EBITDA reached $1.9 million for the first nine months of 2025, up from $1.5 million in the same period of 2024. Cash totaled $232,000 and total assets increased 15.4% to $27.6 million as of September 30, 2025. The company noted continued organic growth, rising patient volumes, and stated that mergers and acquisitions remain a priority. A restatement was made to the 2024 cash flow classification, with no impact on balance sheets, statements of operations, or total cash flows.